Skip to main content
. 2018 Feb 16;2(2):282–290. doi: 10.1002/rth2.12076

Figure 2.

Figure 2

Randomized controlled trial meta‐analyses . Meta‐analyses of 30‐day event rates (A) thromboembolic events (B) major bleeding (C) minor bleeding (D) overall mortality. DOAC, direct oral anticoagulant; VKA, vitamin K antagonist